Upstream Bio, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Upstream Bio's 10-K filing highlights the company's dedication to developing Verekitug, a novel treatment for inflammatory diseases, particularly severe respiratory disorders.